EU Horizon Brain Health Initiative Awards €12M for Non-Invasive Neuromodulation
The European Union's Horizon Europe program has awarded €12 million to a consortium studying transcranial focused ultrasound and photobiomodulation for neurodegenerative disease prevention.
The Grant
The Horizon Europe Framework Programme has funded NEUROMOD-EU, a multi-site consortium led by Charité Universitätsmedizin Berlin, with €12 million over 5 years. The project investigates whether non-invasive brain stimulation technologies can slow or prevent neurodegenerative decline in at-risk populations.
Two technologies are under study:
Transcranial Focused Ultrasound (tFUS): Low-intensity ultrasound pulses directed at specific brain regions. Unlike TMS, tFUS can reach deep brain structures (hippocampus, basal ganglia) with millimeter precision. Early evidence suggests it can modulate neuronal activity, increase BDNF, and enhance glymphatic clearance — the brain's waste-removal system implicated in Alzheimer's pathology.
Transcranial Photobiomodulation (tPBM): Near-infrared light (810nm) applied through the skull. Several small studies have shown cognitive improvements in mild cognitive impairment (MCI) patients, potentially through enhanced mitochondrial function and reduced neuroinflammation. The mechanism is thought to involve cytochrome c oxidase — a mitochondrial enzyme that absorbs near-infrared photons.
Why This Matters
Current neurodegenerative disease treatment is almost entirely pharmaceutical — and largely ineffective at disease modification. No approved drug stops or reverses Alzheimer's progression. The amyloid-targeting antibodies (lecanemab, aducanumab) show modest effects with significant side effect profiles.
Non-invasive neuromodulation represents a fundamentally different approach: instead of targeting specific molecular pathways, these technologies aim to enhance the brain's own maintenance systems — neuroplasticity, waste clearance, mitochondrial function, and neurovascular coupling.
If NEUROMOD-EU demonstrates prevention efficacy, it could establish a new category of "brain maintenance" interventions — analogous to physical exercise for cardiovascular health.
The Study Design
- Population: 600 adults aged 55-75 with at least one Alzheimer's risk factor (ApoE4, family history, subjective cognitive decline)
- Arms: tFUS, tPBM, combined tFUS+tPBM, sham control
- Duration: 24-month intervention with 12-month follow-up
- Primary outcomes: Hippocampal volume (MRI), amyloid and tau PET, cognitive test batteries
- Sites: Berlin, Amsterdam, Barcelona, Milan, London
This is the largest prevention trial of non-invasive neuromodulation for neurodegeneration ever conducted.
€12 million asking whether we can maintain the brain the way we maintain the body — with regular, non-invasive, technology-assisted care.